Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Long-Term Debt Repayments (2017 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $24.9 million as the latest value for Q3 2023.

  • Quarterly Long-Term Debt Repayments changed N/A to $24.9 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $24.9 million through Dec 2024, changed 0.0% year-over-year, with the annual reading at $27.5 million for FY2023, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q3 2023 was $24.9 million at Cartesian Therapeutics, up from $15.1 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $24.9 million in Q3 2023, with the low at $700000.0 in Q3 2019.
  • Average Long-Term Debt Repayments over 3 years is $7.8 million, with a median of $2.1 million recorded in 2019.
  • Peak annual rise in Long-Term Debt Repayments hit 2059.0% in 2020, while the deepest fall reached 2059.0% in 2020.
  • Over 3 years, Long-Term Debt Repayments stood at $2.1 million in 2019, then soared by 619.67% to $15.1 million in 2020, then skyrocketed by 64.57% to $24.9 million in 2023.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $24.9 million, $15.1 million, and $2.1 million for Q3 2023, Q3 2020, and Q2 2020 respectively.